StockData

Cue Biopharma vs Q32 Bio

CUE and QTTB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CUE and QTTB compare

Q32 Bio is the larger company, worth 2.2 times as much as Cue Biopharma ($259M against $117M).

Q32 Bio scores higher on the StockData Score (11 against 8 for Cue Biopharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCUEQTTB
Size and price
Market cap$117M$259M
Share price$16.12$8.71
Change, 1 year−19.5%258%
Change, 5 years−96.4%−90.6%
Beta (5Y)2.340.67
Employees2924
StockData Score
Total score811 (better)
Valuation score03 (better)
Growth score2 (better)1
Performance score11
Health score56 (better)
Dividend score00
Valuation
P/S3.1×–
P/B50.7×0.9× (better)
EV/EBITDA–−1.6×
FCF yield−42.8%–
Fair value–$20.33
Margin of safety–57.1%
Growth
Revenue growth (TTM)354%–
Revenue growth, 5Y average54.2%81.9% (better)
Profitability
Operating margin−262%–
Net margin−436%–
FCF margin−133%–
Return on equity−1603%24.0% (better)
Financial health
Debt / equity0.000.00
Current ratio1.2556.34 (better)
Altman Z-score−30.7116.60 (better)
Piotroski F-score5 (better)4
Dividends and buybacks
Buyback yield–−4.0%
Shareholder yield0.00% (better)−4.0%
Ownership
Held by institutions22.6%74.6%
Held by insiders17.4%28.9%
Insider net buying, 12 months−$2.3M$29.5M (better)
Short interest, % of float14.4%26.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.